^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Nasopharyngeal Carcinoma
    Drug:Tevimbra (tislelizumab-jsgr) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

    Published date:
    12/15/2022
    Excerpt:
    Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers....Recommendation 4.1….Toripalimab, camrelizumab, or tislelizumab, with gemcitabine and cisplatin, should be offered as first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer
    Secondary therapy:
    cisplatin + gemcitabine
    DOI:
    10.1200/JCO.22.02328
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Cancer Cell
    Title:

    Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

    Published date:
    05/18/2023
    Excerpt:
    PFS after next line of treatment and overall survival showed favorable trends for tislelizumab-chemotherapy versus placebo-chemotherapy....Our results support that tislelizumab-chemotherapy should be considered as first-line treatment for R/M NPC, and GEP and activated DC signature results may help identify patients who might benefit most from immunochemotherapy treatment.
    DOI:
    10.1016/j.ccell.2023.04.014
    Trial ID:
    RATIONALE 309